Table 3.
Predictive performance of the risk score for ischemic brain lesions.
| CHA2D-VASc score* | CHA2DS2-VASc score | |
|---|---|---|
| Clinically overt ischemic brain lesions | ||
| C-statistic | 0.622 | NA |
| Brier Score | 0.093 | NA |
| AIC | 1,147 | NA |
| Silent ischemic brain lesions | ||
| C-statistic | 0.582 | NA |
| Brier Score | 0.174 | NA |
| AIC | 1,852 | NA |
| Any ischemic brain lesion | ||
| C-statistic | 0.626 | 0.693 |
| Brier Score | 0.223 | 0.207 |
| AIC | 2,217 | 2,099 |
AIC, Akaike's Information Criteria; NA, not applicable.
*
CHA2D-VASc score was adapted by excluding history of stroke/transient ischemic attack (S2).
Female patients with a CHA2D-VASc score/CHA2DS2-VASc score of 1 were assigned to the category of 0 points.
Clinically overt ischemic brain lesions were defined as ischemic brain lesions in patients with a history of stroke.
Silent ischemic brain lesions were defined as ischemic brain lesions in patients without a history of stroke/TIA.
Any ischemic brain lesion was defined as a composite of clinically overt and silent ischemic brain lesions including ischemic lesions in patients with history of TIA.